Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immucor -- Ignore unavailable to you. Want to Upgrade?

To: sim1 who wrote (119)	7/17/1998 12:22:00 PM
From: Thomas Kirwin	Respond to of 422

Immucor's IBD Statistics Hello, Immucor's statistics regarding EPS, Relative Strength, Accumulation Distribution, etc. have greatly improved as published in the NASDAQ Tables of Investor's Business Daily on Friday, July 17, 1998. Take a look.... EPS Rank - 78 Relative Strength - 70 Accumulation Distribution - B Annual Earnings Growth - +11% Quarter EPS Change - +20% Quarter Sales Change - +5% Group Rank - B Legend EPS Rank - Measures a company's earnings per share growth in the last 5 years and the stability of that growth. The %change in the last two quarters' earnings vs. same quarters a year earlier is combined and averaged with the 5 year record. Result is compared to all companies in the tables and ranked on a scale of 1 to 99, with 99 the highest. A 90 rank means the company produced earnings in the top 10%. Companies with superior earnings records rank 80 or higher. Relative Price Strength - Measures daily each stock's relative price change over the last 12 months compared to all other stocks in the tables. Results are ranked 1 to 99. Stocks ranking below 70 indicate weaker or more laggard relative performance. Accumulation Distribution - Rating takes into account the percent change in a stock's daily price and its volume. "A" is strongest "E" is weakest. Accumulation-Distribution should be used with other fundamental and technical factors to determine investment decisions. Lets go Immucor! Regards, Tom

To: sim1 who wrote (119)	7/18/1998 5:57:00 PM
From: technetx	Read Replies (3) \| Respond to of 422

These tests are for pathogens in the blood. Immucor's devices (ABS, etc.) are for ABO TYPING and antibody detection (Rh factors, etc). Chiron's device and Immucor's devices would complement each other very nicely. What is most significant here is the following statement: "We based our evaluation on the criteria that leading blood banks have defined including: sensitivity, specificity, positive identification of sample, automation and ease of use, rapid throughput and..." Automation, "ease of use", and "rapid throughput" are three things blood banks want. The ABS, DIAS and the ROSYS were made to meet these particular needs. 1999 should be a very interesting year for Immucor !

To: sim1 who wrote (119)	7/25/1998 10:46:00 PM
From: Thomas Kirwin	Respond to of 422

Immucor Canada Web Site While continuing my research on Immucor and its subsidiaries I found the Immucor Canada web site. A quick review reveals that it contains very little in the way of content. There is at least one nugget of useful information such as the quote below: "Immucor has become the recognized leader in many other markets through it's representation of prominent suppliers such as Sakura-Finetek in the histo- pathology lab, Biosite in the point of care drug testing market, Sebia with it's innovative automation of electrophoresis." immucan.com By the way, Ms. Vinson of Immucor's IR Department previously indicated that Immucor Canada is their distributor. Message 4247186 Immucor Canada Press Release - April 24, 1998 Message 4201910 Regards, Tom